Letter to the Editor: Treatment of Covid-19 with Fisetin flavonoid nanoparticles

References

• 1.
  Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, e al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-An update on the status. Mil Med Res 2020; 7: 11-20.
• 2.
  Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: Observations and hypotheses. Lancet 2020; 395: 1517-1520.
• 3.
  Mishra A, Kaur U, Singh A. Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study. J Biomol Struct Dyn 2020; 1-10.
• 4.
  Santana FP, Thevenard F, Gomes KS, Taguchi L, Cmara NO, Stilhano RS, et al. New perspectives on natural flavonoids on COVID19induced lung injuries. Phytother Res 2021; 35: 4988-5006.
• 5.
  Astuti I. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. diabetes and metabolic syndrome. Clin Res Rev 2020; 14: 407-412.
• 6.
  Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444-1448.
• 7.
  Burgos-Blasco B, Gemes-Villahoz N, Santiago JL, Fernandez-Vigo JI, Espino-Paisn L, Sarri B. Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients. Exp Eye Res 2020; 200: 108253-108258.
• 8.
  Bez-Santos YM, John SE, Mesecar AD. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res 2015; 115: 21-38.
• 9.
  Juc MM, Cysne Filho FM, de Almeida JC, Mesquita DD, Barriga JR, Dias KC, et al. Flavonoids: Biological activities and therapeutic potential. Nat Prod Res 2020; 34: 692-705.
• 10.
  Camell CD, Yousefzadeh MJ, Zhu Y, Prata LG, Huggins MA, Pierson M, et al. Senolytics reduce coronavirus-related mortality in old mice. Science 2021; 373: eabe4832.
• 11.
  Crane MJ, Devine S, Jamieson AM. Graphene oxide/silver nanoparticle ink formulations rapidly inhibit influenza A virus and OC43 coronavirus infection in vitro. Bio Rxiv 2021.
• 12.
  Zhao Z, Xiao Y, Xu L, Liu Y, Jiang G, Wang W, et al. Glycyrrhizic acid nanoparticles as antiviral and anti-inflammatory agents for COVID-19 treatment. ACS Appl Mater Interfaces 2021; 13: 20995-21006.
• 13.
  Dourado D, Freire DT, Pereira DT, Amaral-Machado L, Alencar N, de Barros AL, Egito ES. Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials. Biomed Pharmacother 2021; 139: 111578.
• 14.
  Neghab HK, Azadeh SS, Soheilifar MH, Dashtestani F. Nanoformulation-Based antiviral combination therapy for treatment of COVID-19. Avicenna J Med Biotechnol 2020; 12: 255-256.##.